BioAgilytix Global Team
The Trusted Partner for Bioanalytical Science and Services
One Team.
One Mission.
At BioAgilytix, our greatest commitment is to deliver unparalleled quality in bioanalysis. We aim to be the trusted partner for our clients, safeguarding integrity at every step. Through rigorous method validation and strict adherence to accreditation and certification standards, we ensure that our facilities, equipment, personnel, and practices meet the highest benchmarks for quality.
Our commitment to quality, along with our unrivalled scientific expertise and technologies, allow us to provide our partners with the confidence of the most accurate, precise, and comprehensive high-quality bioanalytical testing services—with results that are delivered right on time and right the first time.
360biolabs offers our clients the Australian Advantage for early-phase clinical studies in a trusted market with state-of-the-art laboratories. While our global footprint supports studies from Phase 2-4, with experienced teams delivering bioanalytical solutions for pharmaceutical and biotechnology organisations of all sizes.
Expertise of Our Global Science-Driven Team
With laboratories in most of the leading biotech and pharmaceutical areas in Australia, the United States, and Europe, we provide end-to-end program success.
- 6 Laboratories
- 3 Countries
- 1000+ Team Globally
- 10+ Years of bench experience
End-to-End Bioanalytical Support
Our global team is the ultimate end-to-end bioanalytical force dedicated to helping generate new innovations and life-changing therapeutics for patients around the world. Discover how we support you through your clinical trial phases.
| Discovery Support Preclinical Phase 1 Phase 2 Phase 3+ |
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory. 360biolabs, located in Australia, specialises in early-phase clinical trial offers. The Australian advantage provides a fast pragmatic regulatory environment, internationally recognised quality systems, and an R&D tax incentive that is cost-competitive. Our global team supports a seamless transition of your early-phase clinical assays from Australia to our United States or European laboratories for Phase 2+. |
|---|---|
| Manufacturing |
BioAgilytix has expertise with a wide array of CMC bioanalytical readouts and across many therapeutic modalities under GMP conditions. |
If you have questions on how our global team can support you, the Australian Advantage, sample transfers, or our capabilities, connect with us.
360biolabs' comprehensive capabilities and strategic location in Australia help make BioAgilytix a global leader in end-to-end bioanalytical solutions dedicated to helping generate new innovations and life-changing therapeutics for patients around the world.
